Iranian Red Crescent Medical Journal

Published by: Kowsar

The Efficacy of Aripiprazole versus Risperidone as Augmentation Therapy in the Treatment of the Resistant Obsessive-Compulsive Disorder: A Double-Blind, Randomized Clinical Trial

Fatemeh Assarian 1 , Fatemeh Sadat Ghoreishi 1 , * , Mahbubeh Borna 2 and Mohammadreza Razzaghof 3
Authors Information
1 Assistant Professor, Department of Psychiatry, Kashan University of Medical Sciences, Kashan, IR Iran
2 Department of Psychiatry, Kashan University of Medical Sciences, Kashan, IR Iran
3 School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran; [m.razzaghof@gmail.com]
Article information
  • Iranian Red Crescent Medical Journal: July 2018, 20 (7); e41418
  • Published Online: October 10, 2016
  • Article Type: Research Article
  • Received: August 11, 2016
  • Revised: September 10, 2016
  • Accepted: September 25, 2016
  • DOI: 10.5812/ircmj.41418

To Cite: Assarian F, Ghoreishi F S, Borna M, Razzaghof M. The Efficacy of Aripiprazole versus Risperidone as Augmentation Therapy in the Treatment of the Resistant Obsessive-Compulsive Disorder: A Double-Blind, Randomized Clinical Trial, Iran Red Crescent Med J. 2018 ; 20(7):e41418. doi: 10.5812/ircmj.41418.

Abstract
Copyright © 2016, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Sadock BJ. Sadock, and P. Ruiz, Kaplan and Sadock's Synopsis of Psychiatry. Wolters Kluwer Health; 2014.
  • 2. Sadock BJ. Kaplan & Sadock's comprehensive textbook of psychiatry. 2. Philadelphia: Williams & wilkinslippincott; 2009.
  • 3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436-42. doi: 10.1016/S0140-6736(96)07495-8. [PubMed: 9164317].
  • 4. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):509-17. [PubMed: 10986724].
  • 5. Ahmadvand A. Prevalence of mental disorders in general population of Kashan City. Iranian J Epidemiol. 2010;6(2):16-24.
  • 6. Mohammadi MR, Ghanizadeh A, Rahgozar M, Noorbala AA, Davidian H, Afzali HM, et al. Prevalence of obsessive-compulsive disorder in Iran. BMC Psychiatry. 2004;4:2. doi: 10.1186/1471-244X-4-2. [PubMed: 15018627].
  • 7. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-32. doi: 10.1038/sj.mp.4001823. [PubMed: 16585942].
  • 8. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400-12. doi: 10.1016/j.pnpbp.2005.11.028. [PubMed: 16503369].
  • 9. Dold M, Aigner M, Lanzenberger R, Kasper S. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials]. Fortschr Neurol Psychiatr. 2011;79(8):453-66. doi: 10.1055/s-0031-1273397. [PubMed: 21809258].
  • 10. Hollander E. Obsessive-compulsive and spectrum disorders: Overview and quality of life issues. J clin psychiatr. 1996.
  • 11. Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233-42. [PubMed: 20520787].
  • 12. Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797-803. doi: 10.1097/JCP.0b013e318272677d. [PubMed: 23131885].
  • 13. Carey PD. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable? Int Clini Psychopharmacol. 2012;27(6):321-5. doi: 10.1097/yic.0b013e3283576881.
  • 14. Dhansay Y, Ipser J, Stein DJ. Pharmacotherapy augmentation strategies in treatment‐resistant anxiety disorders. The Cochrane Library; 2005.
  • 15. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17(2):79-93. doi: 10.1016/j.euroneuro.2006.07.002. [PubMed: 16904298].
  • 16. Vulink NC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol. 2011;21(6):429-49. doi: 10.1016/j.euroneuro.2010.12.007. [PubMed: 21345655].
  • 17. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012;29(10):850-4. doi: 10.1002/da.21996. [PubMed: 22933237].
  • 18. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364-72. doi: 10.1016/j.euroneuro.2008.01.001. [PubMed: 18280710].
  • 19. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011;26(1):51-7. doi: 10.1002/hup.1169. [PubMed: 21308781].
  • 20. Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24(5):265-9. doi: 10.1097/YIC.0b013e32832e9b91. [PubMed: 19629012].
  • 21. Kim SW, Dysken MW, Katz R. Rating scales for obsessive compulsive disorder. Psychiatr Ann. 1989;19(2):74-9. doi: 10.3928/0048-5713-19890201-07.
  • 22. Rajezi Esfahani S. Reliability and Validity of the Persian version of the Yale-Brown Obsessive-Compulsive scale (Y-BOCS). Iran J Psychiatr Clin Psychol. 2012;17(4):297-303.
  • 23. Shabani M, Ghoreishi S. Olanzapine Augmentation Therapy in Patients with the Obsessive-Compulsive Disorder Resistant to Treatment. Zanjan Uni Med ASci J. 2009;17(66):21-8.
  • 24. First MB. User's guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version. USA: American Psychiatric Pub; 1997.
  • 25. First MB. User's guide for the structured clinical interview for DSM-IV axis II personality disorders: SCID-II. USA: American Psychiatric Pub; 1997.
  • 26. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-11. [PubMed: 2684084].
  • 27. Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011;7:107-11. doi: 10.2174/1745017901107010107. [PubMed: 21686322].
  • 28. Higuma H, Kanehisa M, Maruyama Y, Ishitobi Y, Tanaka Y, Tsuru J, et al. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. World J Biol Psychiatry. 2012;13(1):14-21. doi: 10.3109/15622975.2010.551667. [PubMed: 22256827].
  • 29. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):49-51. [PubMed: 15669888].
  • 30. Ashton AK. Aripiprazole augmentation of combination escitalopram and sertraline in the treatment of refractory obsessive-compulsive disorder. Psychiatr (Edgmont). 2005;2(1):18.
  • 31. da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1550-1. doi: 10.1016/j.pnpbp.2007.07.008. [PubMed: 17692447].
  • 32. Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2007;68(6):972-3. [PubMed: 17592930].
  • 33. Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(6):688-93. [PubMed: 21105283].
  • 34. Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract. 2011;15(4):263-9. doi: 10.3109/13651501.2011.605958. [PubMed: 22121999].
  • 35. Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31(2):174-9. doi: 10.1097/JCP.0b013e31820e3db6. [PubMed: 21346614].
  • 36. Ozturk M, Coskun M. Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2009;29(6):607-9. doi: 10.1097/JCP.0b013e3181bfe068. [PubMed: 19910732].
  • 37. Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2008;197(4):687-8. doi: 10.1007/s00213-008-1091-1. [PubMed: 18264798].
  • 38. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety. 2008;25(2):172-4. doi: 10.1002/da.20303. [PubMed: 17340610].
  • 39. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69-74. doi: 10.1016/j.euroneuro.2004.04.004. [PubMed: 15572275].
  • 40. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736-43. [PubMed: 15960567].
  • 41. Arias HF. Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors. Actas Espa-Olas De Psiquiatría. 2005;34(3):147-52.
  • 42. Sun TF, Lin PY, Wu CK. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J. 2001;24(9):587-92. [PubMed: 11725630].
  • 43. Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci. 2006;60(3):389-93. doi: 10.1111/j.1440-1819.2006.01519.x. [PubMed: 16732759].
  • 44. McDougle CJALHP. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Arch General Psychiatr. 2002;59(5):472-3. doi: 10.1001/archpsyc.59.5.472.
  • 45. Boricevic Marsanic, V . Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with Risperidone and Clozapine in an adolescent girl-a case report. Collegium Antropologicum. 2011;35(1):293-6.
  • 46. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360(9330):397-405. doi: 10.1016/S0140-6736(02)09620-4. [PubMed: 12241794].
  • 47. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155(7):921-8. doi: 10.1176/ajp.155.7.921. [PubMed: 9659858].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments